Prasad Raju 4

What Happened
Prasad Raju, Chief Financial Officer of CRISPR Therapeutics (CRSP), exercised 34,972 stock options and immediately sold those 34,972 shares. He paid $45.15 per share to exercise (total cost $1,578,986) and sold the shares in the open market at a weighted average price of $60.19 for total gross proceeds of $2,104,965 — a net difference of approximately $525,979 before taxes and fees. The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: January 22, 2026 (reported on Form 4 filed January 26, 2026 — timely).
• Exercise: 34,972 shares at $45.15/share (total $1,578,986).
• Sale: 34,972 shares at weighted avg $60.19/share (total $2,104,965); sales prices ranged $60.00–$60.42.
• Net cash difference (sale proceeds minus exercise cost): ≈ $525,979 (pre-tax, pre-fees).
• Shares owned after transaction: not specified in the provided filing.
• Notable footnotes: (F1) sales were under a 10b5-1 trading plan adopted Aug 18, 2025; (F2) reported sale price is a weighted average across multiple trades; (F3) the options were granted Mar 14, 2023 (100,000 options) with a multi-year vesting schedule.
• Filing timeliness: Form 4 filed on Jan 26, 2026, which meets the usual two-business-day filing requirement.

Context
This was an exercise-and-sell sequence (options exercised then shares sold) executed under a pre-set 10b5-1 plan, a common mechanism executives use to sell shares at predetermined times. The 10b5-1 disclosure indicates the sales were made pursuant to a prior plan rather than an ad-hoc decision; this is informational and not a statement about insider intent.